优化肿瘤坏死因子抑制剂在免疫介导的炎症性疾病管理中的应用。

Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases.

作者信息

Bressler Brian, Haraoui Boulos, Keystone Edward, Sette Alessandro

机构信息

Division of Gastroenterology, University of British Columbia, Vancouver, BC, Canada.

出版信息

J Rheumatol Suppl. 2010 May;85:40-52. doi: 10.3899/jrheum.091464.

DOI:10.3899/jrheum.091464

PMID:20436164

Abstract

The introduction of anti-tumor necrosis factor (TNF) therapies has dramatically improved the treatment of immune-mediated inflammatory diseases and provides treatment options for patients who do not respond to conventional disease-modifying antirheumatic drugs. However, the use of anti-TNF therapies still needs to be optimized. Dropoff rates, patients' lack of response, and toxicity are issues that need to be addressed to render these therapies more effective for more patients.

摘要

抗肿瘤坏死因子（TNF）疗法的引入显著改善了免疫介导的炎症性疾病的治疗，并为对传统抗风湿药物无反应的患者提供了治疗选择。然而，抗TNF疗法的使用仍需优化。停药率、患者无反应以及毒性等问题需要得到解决，以使这些疗法对更多患者更有效。